No results for ‘’
Transgene Biotek Ltd
₹2.85
(2.89%)
Tue, 25 Aug 2026, 07:22 pm
Health Technology
Biotechnology
24.5KTransgene Biotek Price to Cash Flow Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 292.69 | 97.62 | 72.26 | 54.80 | 298.96 | 528.57 | 17.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 2.11 | 1.10 | 0.61 | 0.19 | 0.98 | 0.70 | 0.69 | 0.04 | 0.18 | 0.08 | 0.08 | 0.23 | 0.30 | 0.69 | 0.70 | 1.56 | 1.57 | 1.66 | 5.76 | 2.53 |
| Price to sales ratio | 134 | 59.42 | 17.97 | 5.68 | 28.40 | 6.82 | 7.54 | 0.83 | 34.98 | 44.79 | 77.06 | 48.56 | 133.93 | 425.15 | 6380 | 204.68 | 315.51 | 342.50 | 262.57 | 97.36 |
| Price to cash flow ratio | 251.79 | 69.89 | 0 | 14.19 | 27.84 | 0 | 10.12 | 0.98 | 4.98 | 4.11 | 2.11 | 615.18 | 7.22 | 0 | 0 | 0 | 0 | 0 | 0 | 17.42 |
| Enterprise value | 241Cr | 133Cr | 85.31Cr | 34.19Cr | 128Cr | 84.94Cr | 219Cr | 34.85Cr | 46.89Cr | 28.84Cr | 28.89Cr | 29.59Cr | 25.58Cr | 39.34Cr | 33.09Cr | 46.01Cr | 39.35Cr | 31.98Cr | 75.67Cr | 39.62Cr |
| Enterprise value to EBITDA ratio | 1020 | 464.03 | 47.74 | 20.76 | 78.07 | 35.89 | 194.62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0.12 | 0.12 | 0.16 | 0.12 | 0.13 | 0.09 | 0.07 | 0.07 | 0.06 | 0.08 | 0.09 | 0.27 | 0.19 | 0.21 | 0.32 | 0.51 | 0.69 | 1.15 | 1.31 | 1.45 |
| Return on equity % | 0 | 1.14 | 0.85 | 0.33 | 0.33 | 0.08 | 4.41 | -0.64 | -50.54 | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38 | -52.51 | -41.80 | -5.94 | -6.52 |
Transgene Biotek Ltd Price to Cash Flow Ratio
The Transgene Biotek Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Transgene Biotek Ltd's valuation, profitability, and overall financial performance. Tracking the Transgene Biotek Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Transgene Biotek Ltd (NSE: , BSE: 526139) is currently trading at ₹2.85, with a market capitalization of ₹18.28Cr. As a leading company in the Health technology sector and Biotechnology industry, monitoring the Transgene Biotek Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Transgene Biotek Ltd Price to Cash Flow Ratio Current Value
The current Transgene Biotek Ltd Price to Cash Flow Ratio stands at 17.42.
The latest Transgene Biotek Ltd Price to Cash Flow Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Transgene Biotek Ltd Price to Cash Flow Ratio Historical Trend
The Transgene Biotek Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 17.42
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0
The recent rise in Transgene Biotek Ltd Price to Cash Flow Ratio suggests strengthening valuation trends and improving market sentiment.
What Transgene Biotek Ltd Price to Cash Flow Ratio Indicates for Investors
The Transgene Biotek Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Transgene Biotek Ltd Price to Cash Flow Ratio Analysis Summary
The Transgene Biotek Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Transgene Biotek Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Transgene Biotek Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.